BCOP Updates 2026: Don't Break My Heart: Cardio-monitoring and Prevention of Treatment-induced Cardiovascular Toxicity in Oncology
In this session the use of traditional cardiac monitoring tests compared to the most recent data driven recommendations on cardiac monitoring will be discussed. Pharmaco-therapeutic interventions that address chemotherapy and targeted therapy-related cardiovascular disease will be compared to highlight new strategies for treatment/prevention of cardiovascular toxicity.
BCOP Updates 2026: Don't Break My Heart: Cardio-monitoring and Prevention of Treatment-induced Cardiovascular Toxicity in Oncology
Authors: Rodney Hunter, PharmD, BCOP, and Jennifer McDonald, PharmD, BCOP
Learning Objectives
- Explain the mechanism of cardiotoxicity associated with anthracyclines, HER-2 targeted inhibitors, and immune checkpoint inhibitors
- Evaluate the benefits of left ventricular ejection fraction (LVEF) and lab monitoring assessment tools for prevention of cardiotoxicity during treatment
- Discuss the limitations of the clinical use of beta blockers and ACE inhibitors for prevention of cardiovascular toxicity
- Compare and contrast interventions for prevention of anthracycline, HER-2 targeted inhibitor, and immune checkpoint inhibitor induced cardiovascular toxicity
Get it now!
Knowledge Course for Pharmacists
Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.
All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.